ATE524070T1 - Verfahren zur verwendung von aus fettgewebe stammenden zellen bei der behandlung von herz- kreislauf-leiden - Google Patents

Verfahren zur verwendung von aus fettgewebe stammenden zellen bei der behandlung von herz- kreislauf-leiden

Info

Publication number
ATE524070T1
ATE524070T1 AT04713403T AT04713403T ATE524070T1 AT E524070 T1 ATE524070 T1 AT E524070T1 AT 04713403 T AT04713403 T AT 04713403T AT 04713403 T AT04713403 T AT 04713403T AT E524070 T1 ATE524070 T1 AT E524070T1
Authority
AT
Austria
Prior art keywords
treatment
cells derived
cardiovascular diseases
fat tissue
patient
Prior art date
Application number
AT04713403T
Other languages
English (en)
Inventor
John Fraser
Marc Hedrick
Min Zhu
Brian Strem
Eric Daniels
Isabella Wulur
Original Assignee
Cytori Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32912320&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE524070(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cytori Therapeutics Inc filed Critical Cytori Therapeutics Inc
Application granted granted Critical
Publication of ATE524070T1 publication Critical patent/ATE524070T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3839—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by the site of application in the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/069—Vascular Endothelial cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
    • C12N2506/1346—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells
    • C12N2506/1384—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells from adipose-derived stem cells [ADSC], from adipose stromal stem cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Botany (AREA)
  • Dermatology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT04713403T 2003-02-20 2004-02-20 Verfahren zur verwendung von aus fettgewebe stammenden zellen bei der behandlung von herz- kreislauf-leiden ATE524070T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US44927903P 2003-02-20 2003-02-20
US46291103P 2003-04-15 2003-04-15
PCT/US2004/005117 WO2004074457A2 (en) 2003-02-20 2004-02-20 Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions

Publications (1)

Publication Number Publication Date
ATE524070T1 true ATE524070T1 (de) 2011-09-15

Family

ID=32912320

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04713403T ATE524070T1 (de) 2003-02-20 2004-02-20 Verfahren zur verwendung von aus fettgewebe stammenden zellen bei der behandlung von herz- kreislauf-leiden

Country Status (13)

Country Link
EP (2) EP2422622B1 (de)
JP (1) JP4971787B2 (de)
KR (2) KR101310578B1 (de)
AT (1) ATE524070T1 (de)
AU (1) AU2004213858B2 (de)
BR (1) BRPI0407694A (de)
CA (1) CA2516510C (de)
DK (1) DK1599575T3 (de)
ES (1) ES2373551T3 (de)
IL (2) IL170354A (de)
MX (1) MXPA05009044A (de)
RU (1) RU2372924C2 (de)
WO (1) WO2004074457A2 (de)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030007954A1 (en) 1999-04-12 2003-01-09 Gail K. Naughton Methods for using a three-dimensional stromal tissue to promote angiogenesis
US7771716B2 (en) 2001-12-07 2010-08-10 Cytori Therapeutics, Inc. Methods of using regenerative cells in the treatment of musculoskeletal disorders
US7585670B2 (en) 2001-12-07 2009-09-08 Cytori Therapeutics, Inc. Automated methods for isolating and using clinically safe adipose derived regenerative cells
US7514075B2 (en) 2001-12-07 2009-04-07 Cytori Therapeutics, Inc. Systems and methods for separating and concentrating adipose derived stem cells from tissue
US20050095228A1 (en) 2001-12-07 2005-05-05 Fraser John K. Methods of using regenerative cells in the treatment of peripheral vascular disease and related disorders
US9597395B2 (en) 2001-12-07 2017-03-21 Cytori Therapeutics, Inc. Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions
KR100930139B1 (ko) 2001-12-07 2009-12-07 사이토리 테라퓨틱스, 인크. 처리된 리포애스퍼레이트 세포로 환자를 치료하기 위한시스템 및 방법
US7595043B2 (en) 2001-12-07 2009-09-29 Cytori Therapeutics, Inc. Method for processing and using adipose-derived stem cells
US20050048035A1 (en) 2001-12-07 2005-03-03 Fraser John K. Methods of using regenerative cells in the treatment of stroke and related diseases and disorders
ES2633604T3 (es) * 2003-09-17 2017-09-22 Cytori Therapeutics, Inc. Métodos para usar células regenerativas derivadas de adiposo en el tratamiento de una enfermedad vascular periférica
JP2007508018A (ja) 2003-10-08 2007-04-05 べト−ステム インコーポレイテッド 新規の幹細胞組成物の調製法および使用法、ならびにこの組成物を含有するキット
JP4731556B2 (ja) * 2004-07-02 2011-07-27 サイトリ セラピューティクス インコーポレイテッド 臨床的に安全な脂肪組織由来再生細胞を単離し、使用するためのシステムおよび方法
DE602005026866D1 (de) * 2004-11-22 2011-04-21 Theregen Inc Vewendung von dreidimensionalem kultiviertem gewebe zur behandlung von kongestivem herzversagen
WO2006074075A2 (en) 2004-12-30 2006-07-13 Primegen Biotech, Llc Adipose-derived stem cells for tissue regeneration and wound healing
KR100811537B1 (ko) 2005-03-11 2008-03-20 양영일 지방조직 치료제의 조성, 이들 제조방법 및 그의 전달방법
AU2013216683B2 (en) * 2005-05-25 2016-06-23 Cytori Therapeutics, Inc. Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions
DE602005026724D1 (de) * 2005-05-25 2011-04-14 Cytori Therapeutics Inc Verfahren zur verwendung von aus fettgewebe stammenden zellen bei der behandlung von herz-kreislauf-leiden
RU2355325C2 (ru) * 2006-08-01 2009-05-20 Федеральное государственное учреждение Новосибирский научно-исследовательский институт патологии кровообращения имени акад. Е.Н. Мешалкина Федерального агентства по высокотехнологичной медицинской помощи Способ лечения инфаркта миокарда
MX2010003019A (es) * 2007-09-19 2010-04-30 Pluristem Ltd Celulas adherentes de los tejidos adiposo y de placenta y uso de las mismas en la terapia.
KR101046188B1 (ko) * 2007-11-30 2011-07-04 주식회사 알앤엘바이오 탈락막 또는 지방 유래 줄기세포를 함유하는 요실금의 세포치료제
JP5015865B2 (ja) * 2008-06-09 2012-08-29 オリンパス株式会社 脂肪組織洗浄装置
KR20100008763A (ko) * 2008-07-16 2010-01-26 주식회사 알앤엘바이오 지방조직 유래 다분화능 줄기세포의 배양물 및 그 추출 단백질을 함유한 화장료용 조성물
WO2010021993A1 (en) 2008-08-19 2010-02-25 Cytori Therapeutics, Inc. Methods of using adipose tissue-derived cells in the treatment of the lymphatic system and malignant disease
AU2010242780B2 (en) 2009-05-01 2016-04-21 Puregraft Llc Systems, methods and compositions for optimizing tissue and cell enriched grafts
JP5710885B2 (ja) * 2010-02-25 2015-04-30 オリンパス株式会社 脂肪由来細胞の賦活化方法および移植材の製造方法
WO2012018127A1 (ja) * 2010-08-06 2012-02-09 国立大学法人大阪大学 膵島と脂肪組織由来幹細胞を利用した膵島移植
JP2014500538A (ja) 2010-10-12 2014-01-09 タニス，ケヴィン ジェイ． 医療機器
US20150044179A1 (en) * 2012-02-24 2015-02-12 Masanori Saeki Cell preparation including fat cell
EP2837682B1 (de) 2012-04-13 2017-09-20 Jeong Chan Ra Verwendung von aspirin in zusammensetzung zur prävention von stammzellendisruption und -aggregation
CN104661601B (zh) 2012-05-22 2018-06-22 史密夫及内修公开有限公司 用于伤口治疗的设备和方法
EP2677024B1 (de) 2012-06-22 2019-11-20 Human Med AG Vorrichtung zum Separieren von adulten Stammzellen
RU2522778C2 (ru) * 2012-10-08 2014-07-20 Федеральное государственное бюджетное учреждение "Российский кардиологический научно-производственный комплекс" Министерства здравоохранения Российской Федерации Средство для лечения ишемических поражений тканей и способ его применения
RU2015143724A (ru) 2013-03-14 2017-04-17 Смит Энд Нефью Инк. Системы и способы применения терапии с использованием пониженного давления
US9737649B2 (en) 2013-03-14 2017-08-22 Smith & Nephew, Inc. Systems and methods for applying reduced pressure therapy
US9580678B2 (en) 2013-06-21 2017-02-28 The Regents Of The University Of California Microfluidic tumor tissue dissociation device
US12133789B2 (en) 2014-07-31 2024-11-05 Smith & Nephew, Inc. Reduced pressure therapy apparatus construction and control
WO2017062042A1 (en) 2015-10-07 2017-04-13 Smith & Nephew, Inc. Systems and methods for applying reduced pressure therapy
US10722540B1 (en) 2016-02-01 2020-07-28 The Regents Of The University Of California Microfluidic device and method for shear stress-induced transformation of cells
JP2019508124A (ja) 2016-02-12 2019-03-28 スミス アンド ネフュー インコーポレイテッド 減圧療法の動作条件を検出するシステムおよび方法
RU2627606C1 (ru) * 2016-05-05 2017-08-09 Константин Валентинович Котенко Способ обработки липоаспирата
AU2017261814B2 (en) 2016-05-13 2022-05-19 Smith & Nephew, Inc. Automatic wound coupling detection in negative pressure wound therapy systems
CN109564231B (zh) 2016-06-08 2023-01-06 加利福尼亚大学董事会 用于处理组织和细胞的方法和装置
US12263294B2 (en) 2016-09-28 2025-04-01 T.J.Smith And Nephew, Limited Systems and methods for operating negative pressure wound therapy devices
AU2017335635B2 (en) 2016-09-29 2023-01-05 Smith & Nephew, Inc. Construction and protection of components in negative pressure wound therapy systems
CN110545766A (zh) 2017-03-07 2019-12-06 史密夫和内修有限公司 包括天线的减压治疗系统和方法
WO2019014141A1 (en) 2017-07-10 2019-01-17 Smith & Nephew, Inc. SYSTEMS AND METHODS FOR INTERACTING DIRECTLY WITH A COMMUNICATION MODULE OF A WOUND PROCESSING APPARATUS
CN108277152B (zh) * 2018-04-04 2023-10-13 博品(上海)生物医药科技有限公司 细胞复苏用无菌换液装置及利用该装置进行细胞复苏换液的方法
GB201820668D0 (en) 2018-12-19 2019-01-30 Smith & Nephew Inc Systems and methods for delivering prescribed wound therapy
EP3931840A1 (de) 2019-02-27 2022-01-05 T.J.Smith And Nephew, Limited Systeme und verfahren zur synchronisierung einer geräteuhr in systemen zur wundüberwachung und/oder behandlung
GB201911693D0 (en) 2019-08-15 2019-10-02 Smith & Nephew Systems and methods for monitoring essential performance of wound therapy
EP4101440A4 (de) * 2020-02-04 2024-02-21 Hierabio Inc. Zusammensetzung zur intraperikardialen injektion mit stammzellen und deren verwendung
KR102844218B1 (ko) 2021-02-09 2025-08-11 인제대학교 산학협력단 심혈관 질환 치료를 위한 양막 유래 중간엽 줄기세포 전달체
EP4327579A1 (de) 2021-04-21 2024-02-28 T.J. Smith and Nephew, Limited Kommunikationssysteme und verfahren für unterdruckwundtherapievorrichtungen

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4000275A (en) * 1969-11-24 1976-12-28 Eli Lilly And Company Immunosuppressants
US4346703A (en) 1979-01-23 1982-08-31 Baxter Travenol Laboratories, Inc. Solution container for continuous ambulatory peritoneal dialysis
US5034135A (en) 1982-12-13 1991-07-23 William F. McLaughlin Blood fractionation system and method
US5372945A (en) 1985-06-06 1994-12-13 Alchas; Paul G. Device and method for collecting and processing fat tissue and procuring microvessel endothelial cells to produce endothelial cell product
US4963489A (en) * 1987-04-14 1990-10-16 Marrow-Tech, Inc. Three-dimensional cell and tissue culture system
US5641622A (en) 1990-09-13 1997-06-24 Baxter International Inc. Continuous centrifugation process for the separation of biological components from heterogeneous cell populations
US5234608A (en) 1990-12-11 1993-08-10 Baxter International Inc. Systems and methods for processing cellular rich suspensions
JP3388352B2 (ja) 1991-10-18 2003-03-17 バクスター、インターナショナル、インコーポレイテッド 骨髄キット
ZA932660B (en) * 1992-04-17 1993-10-26 Sankyo Co Derivatives of adipogenesis inhibitory factor, their preparation and their use
US6017719A (en) 1994-06-14 2000-01-25 Nexell Therapeutics, Inc. Positive and positive/negative cell selection mediated by peptide release
US6238908B1 (en) 1995-06-07 2001-05-29 Aastrom Biosciences, Inc. Apparatus and method for maintaining and growth biological cells
FR2742662B1 (fr) 1995-12-21 1998-01-23 Centre Nat Rech Scient Anticorps anti-idiotypiques du facteur de croissance endotheliale vasculaire et leur utilisation comme medicaments
US5830714A (en) 1996-04-17 1998-11-03 Molecular Biology Resources, Inc. Biologically active fragment of bacillus stearothermophilus DNA polymerase
US5869037A (en) * 1996-06-26 1999-02-09 Cornell Research Foundation, Inc. Adenoviral-mediated gene transfer to adipocytes
CA2272244A1 (en) 1996-11-19 1998-05-28 Roche Diagnostics Gmbh Recombinant collagenase type i from clostridium histolyticum and its use for isolating cells and groups of cells
US5830741A (en) 1996-12-06 1998-11-03 Boehringer Mannheim Corporation Composition for tissue dissociation containing collagenase I and II from clostridium histolyticum and a neutral protease
US6451207B1 (en) 1997-06-04 2002-09-17 Dexter Magnetic Technologies, Inc. Magnetic cell separation device
EP1003847A4 (de) 1997-09-04 2005-04-06 Science Res Lab Inc Zelltrennung mittels elektrischer felder
US6251295B1 (en) 1998-01-08 2001-06-26 Nexell Therapeutics Inc. Method for recirculation washing of blood cells
US6001642A (en) 1998-06-29 1999-12-14 Wyle Laboratories, Inc. Life Sciences Bioreactor and cell culturing processes using the bioreactor
DE19841835C2 (de) 1998-09-12 2003-05-28 Fresenius Ag Zentrifugenkammer für einen Zellseparator
KR100979664B1 (ko) * 1999-03-10 2010-09-02 유니버시티 오브 피츠버그 오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 지방 유래 간세포 및 격자
US6316247B1 (en) 1999-06-15 2001-11-13 University Of Pittsburgh System and method for refining liposuctioned adipose tissue
US7094874B2 (en) 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
EP1361896A2 (de) * 2001-01-23 2003-11-19 Boston Scientific Corporation Methode zur lokalen myocardialen injektion zur behandlung ischämischen myocardiums
US20030054331A1 (en) * 2001-09-14 2003-03-20 Stemsource, Inc. Preservation of non embryonic cells from non hematopoietic tissues
KR100930139B1 (ko) * 2001-12-07 2009-12-07 사이토리 테라퓨틱스, 인크. 처리된 리포애스퍼레이트 세포로 환자를 치료하기 위한시스템 및 방법
US20050250202A1 (en) * 2002-03-19 2005-11-10 March Keith L Adipose stromal stem cells for tissue and vascular modification
DE602004024125D1 (de) * 2003-12-25 2009-12-24 Kanazawa University Technology Induktion einer myokardzelle unter verwendung einer säuger-knochenmarkzelle oder aus nabelschnurblut stammenden zelle und fettgewebe

Also Published As

Publication number Publication date
EP2422622A1 (de) 2012-02-29
WO2004074457A3 (en) 2006-05-18
WO2004074457A2 (en) 2004-09-02
KR101310578B1 (ko) 2013-09-23
KR20050109941A (ko) 2005-11-22
DK1599575T3 (da) 2012-01-16
IL214373A (en) 2014-09-30
EP1599575B1 (de) 2011-09-14
ES2373551T3 (es) 2012-02-06
AU2004213858B2 (en) 2009-01-22
EP2422622B1 (de) 2017-01-11
EP1599575A2 (de) 2005-11-30
BRPI0407694A (pt) 2006-03-01
CA2516510A1 (en) 2004-09-02
JP2007525422A (ja) 2007-09-06
AU2004213858A1 (en) 2004-09-02
CA2516510C (en) 2012-07-10
HK1102085A1 (en) 2007-11-02
KR20120038534A (ko) 2012-04-23
EP1599575A4 (de) 2007-08-08
EP1599575B9 (de) 2012-03-14
RU2005128964A (ru) 2006-03-20
MXPA05009044A (es) 2006-03-17
RU2372924C2 (ru) 2009-11-20
IL170354A (en) 2011-07-31
JP4971787B2 (ja) 2012-07-11
IL214373A0 (en) 2011-09-27

Similar Documents

Publication Publication Date Title
ATE524070T1 (de) Verfahren zur verwendung von aus fettgewebe stammenden zellen bei der behandlung von herz- kreislauf-leiden
ATE500319T1 (de) Verfahren zur verwendung von aus fettgewebe stammenden zellen bei der behandlung von herz- kreislauf-leiden
WO2006014159A3 (en) Methods of using regenerative cells in the treatment of musculoskeletal disorders
WO2005034843A3 (en) Methods of using regenerative cells in the treatment of peripheral vascular disease and related disorders
ATE355852T1 (de) Verwendung von botulinum toxin zur behandlung von herz- und kreislaufskrankheiten
DE602004031782D1 (de) Verfahren zur verwendung regenerativer zellen zur förderung der wundheilung
ATE432693T1 (de) Kombinationstherapie zur behandlung von diabetes und dadurch bedingten leiden sowie zur behandlung von mittels erhöhung des glp-1-spiegels im blut verbesserten leiden
DE502005010615D1 (de) Mittel zur behandlung von entzündlichen erkrankungen
DE602005019144D1 (de) Verfahren zur schmerzbehandlung in knochenkrebs du
ATE455574T1 (de) Prä-exzitations-pacing zur behandlung von hypertonie
EP2305276A3 (de) Zellen aus Lipoaspirat und ihre Verwendung zur Therapie
MX2018013476A (es) Composiciones para tratar trastornos acido-base.
DE602005026866D1 (de) Vewendung von dreidimensionalem kultiviertem gewebe zur behandlung von kongestivem herzversagen
EP1499190A4 (de) Verfahren zur behandlung von lebererkrankungen und leberschäden mit wachstumshormon und foxm1b
DE10390950D2 (de) Vorrichtung zur Behandlung von Patienten mittels Hirnstimulation
ATE478942T1 (de) Verfahren zur verwendung regenerativer zellen bei der behandlung von nierenkrankheiten und störungen
DE602004030661D1 (de) Verwendung von kahalalide verbindungen zur herstellung eines arzneimittels zur behandlung von psoriasis
ATE395073T1 (de) Behandlung von nicht-alkoholischer steatotischer hepatitis (nash)
DE602004016547D1 (de) 1,4-dihydropyridinverbindungen, pharmazeutische verbindungen, und verfahren zur behandlung von herzkreislauferkrankungen
ATE526984T1 (de) Knochen-morphogenetische proteine zur verwendung zur behandlung und prävention von neuroblastomen
DE602004015321D1 (de) 1,4-dihydropyridinverbindungen, pharmazeutische verbindungen, und verfahren zur behandlung von herzkreislauferkrankungen
Raganowicz et al. Testing the differences in bioelectrical potentials occurring in distractive osteogenesis: Human and animal clinical research
WO2010123942A3 (en) Materials and methods for using adipose stem cells to treat lung injury and disease
GB0501156D0 (en) General cure to diseases idea 3

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties